Ayala Pharmaceuticals, Inc. (AYLA) |
|
0.5339 0 (0%)
|
01-18 15:56 |
|
Open: |
0.4876 |
Pre. Close: |
0.5339 |
|
High:
|
0.5698 |
Low:
|
0.4399 |
|
Volume:
|
137,793 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2023-03-03 4:47:42 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.68 One year: 0.8 |
| Support: |
Support1: 0.44 Support2: 0.35 |
| Resistance: |
Resistance1: 0.59 Resistance2: 0.68 |
| Pivot: |
0.5  |
| Moving Average: |
MA(5): 0.5 MA(20): 0.48
MA(100): 0.74  MA(250): 1.81 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 52.1 %D(3): 56.4 |
| RSI: |
RSI(14): 50.2 |
| 52-week: |
High: 6.09 Low: 0.35 |
| Average Vol(K): |
3-Month: 54 (K) 10-Days: 31 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AYLA ] has closed above bottom band by 44.0%. Bollinger Bands are 76.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 57 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.5 - 0.51 |
0.51 - 0.51 |
|
Low:
|
0.5 - 0.5 |
0.5 - 0.5 |
|
Close:
|
0.5 - 0.5 |
0.5 - 0.51 |
|
Company Description |
|
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel. |
Headline News |
Wed, 25 Jan 2023
AYALA PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Thu, 19 Jan 2023
Advaxis and Ayala Pharmaceuticals Complete Merger - Yahoo Finance
Wed, 18 Jan 2023
Ayala sees last day of trading as merger with Advaxis takes place ... - Seeking Alpha
Thu, 05 Jan 2023
Does Sarepta Therapeutics Inc (SRPT) Have What it Takes to be in ... - InvestorsObserver
Thu, 05 Jan 2023
Twist Bioscience Corp (TWST) Stock Is Up 14.64% This Week: Buy, Hold, or Sell? - InvestorsObserver
Thu, 05 Jan 2023
Where Does Vyne Therapeutics Inc (VYNE) Stock Fall in the Biotechnology Field After It Has Gained 35.71% This Week? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
15 (M) |
|
% Held by Insiders
|
6.9e+006 (%) |
|
% Held by Institutions
|
29.7 (%) |
|
Shares Short
|
149 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.739e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
166.3 |
|
Return on Equity (ttm)
|
-78.3 |
|
Qtrly Rev. Growth
|
1.73e+006 |
|
Gross Profit (p.s.)
|
-42.92 |
|
Sales Per Share
|
-81.34 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-2.8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-34 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
1.69 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
48230 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
